Macrolide-Resistant Mycoplasma genitalium in Southeastern Region of the Netherlands, 2014-2017
Mycoplasma genitalium infections of the urogenital tract are usually treated with azithromycin; however, for the past several years, rates of azithromycin treatment failure have increased. To document the occurrence and frequency of macrolide resistance-mediating mutations (MRMMs) in M. genitalium infections, we collected 894 M. genitalium-positive samples during April 2014-December 2017 and retrospectively tested them for MRMMs. We designated 67 samples collected within 6 weeks after a positive result as test-of-cure samples; of these, 60 were MRMM positive. Among the remaining 827 samples, the rate of MRMM positivity rose from 22.7% in 2014 and 22.3% in 2015 to 44.4% in 2016 but decreased to 39.7% in 2017. Because of these high rates of MRMMs in M. genitalium infections, we recommend that clinicians perform tests of cure after treatment and that researchers further explore the clinical consequences of this infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Emerging infectious diseases - 25(2019), 7 vom: 02. Juli, Seite 1297-1303 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Martens, Liesbeth [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.12.2019 Date Revised 09.03.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3201/eid2507.181556 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM298279398 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM298279398 | ||
| 003 | DE-627 | ||
| 005 | 20231225093820.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3201/eid2507.181556 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0994.xml |
| 035 | |a (DE-627)NLM298279398 | ||
| 035 | |a (NLM)31211669 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Martens, Liesbeth |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Macrolide-Resistant Mycoplasma genitalium in Southeastern Region of the Netherlands, 2014-2017 |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.12.2019 | ||
| 500 | |a Date Revised 09.03.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Mycoplasma genitalium infections of the urogenital tract are usually treated with azithromycin; however, for the past several years, rates of azithromycin treatment failure have increased. To document the occurrence and frequency of macrolide resistance-mediating mutations (MRMMs) in M. genitalium infections, we collected 894 M. genitalium-positive samples during April 2014-December 2017 and retrospectively tested them for MRMMs. We designated 67 samples collected within 6 weeks after a positive result as test-of-cure samples; of these, 60 were MRMM positive. Among the remaining 827 samples, the rate of MRMM positivity rose from 22.7% in 2014 and 22.3% in 2015 to 44.4% in 2016 but decreased to 39.7% in 2017. Because of these high rates of MRMMs in M. genitalium infections, we recommend that clinicians perform tests of cure after treatment and that researchers further explore the clinical consequences of this infection | ||
| 650 | 4 | |a Historical Article | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Mycoplasma genitalium | |
| 650 | 4 | |a antimicrobial resistance | |
| 650 | 4 | |a bacteria | |
| 650 | 4 | |a macrolide resistance | |
| 650 | 4 | |a molecular diagnostics | |
| 650 | 4 | |a sexually transmitted disease | |
| 650 | 4 | |a the Netherlands | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Macrolides |2 NLM | |
| 700 | 1 | |a Kuster, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a de Vos, Wilco |e verfasserin |4 aut | |
| 700 | 1 | |a Kersten, Maikel |e verfasserin |4 aut | |
| 700 | 1 | |a Berkhout, Hanneke |e verfasserin |4 aut | |
| 700 | 1 | |a Hagen, Ferry |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging infectious diseases |d 1995 |g 25(2019), 7 vom: 02. Juli, Seite 1297-1303 |w (DE-627)NLM088704254 |x 1080-6059 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2019 |g number:7 |g day:02 |g month:07 |g pages:1297-1303 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3201/eid2507.181556 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2019 |e 7 |b 02 |c 07 |h 1297-1303 | ||